CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel...

詳細記述

保存先:
書誌詳細
出版年:Biomark Res
主要な著者: Cuesta-Mateos, Carlos, Fuentes, Patricia, Schrader, Alexandra, Juárez-Sánchez, Raquel, Loscertales, Javier, Mateu-Albero, Tamara, Vega-Piris, Lorena, Espartero-Santos, Marina, Marcos-Jimenez, Ana, Sánchez-López, Blanca Andrea, Pérez-García, Yaiza, Jungherz, Dennis, Oberbeck, Sebastian, Wahnschaffe, Linus, Kreutzman, Anna, Andersson, Emma I., Mustjoki, Satu, Faber, Edgar, Urzainqui, Ana, Fresno, Manuel, Stamatakis, Kostantino, Alfranca, Arantzazu, Terrón, Fernando, Herling, Marco, Toribio, María Luisa, Muñoz-Calleja, Cecilia
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2020
主題:
Rapid Communication
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585232/
https://ncbi.nlm.nih.gov/pubmed/33110606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00234-z
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料